Page 11 - Pharma Industry

No Indian Pharma company in world Access to Medicine Index

GSK, J&J, Novartis, Merck are among top 20 firms working towards making available essential drugs in low- and middle-income countries

Pharma profits hit in US this quarter

Firms like Dr Reddy's and Cadila have seen US revenues dip due to heavy pressure on generics market

Domestic pharma firms zoom past MNCs in growth, market share

Indian firms enjoy 77% share, post 12.6% growth against 7.9% by MNCs, with superior penetration, brand recall, marketing

Cipla, Wockhardt join global initiative on tackling drug resistant infections

Spread of drug-resistant infections could hit the global economy even harder than the the 2008 financial crisis

Price overcharge: One-time settlement likely for pharma firms

Dept of pharmaceuticals, finance ministry to work together on quantum of waiver on interest payment

Centre keen to adopt Gujarat model of SMS-alert for 'unsafe' drugs

There are 27,000 pharmacy outlets in Gujarat, they can stop selling unsafe drugs after aberrations are detected in the batch

Indian pharma market crosses Rs 1 lakh cr MAT; growth slows

Price control, ban on fixed dose combinations cited as reasons for slower growth

Pharma sector grows 7.7% in May; FDC ban weighs

Diabetic, neurology and cardiac segments beat overall pharma market growth by 250-700 bps, gastro and anti-infective were laggards According to data from the AIOCD-AWACS, the market research wing of the All India Organisation of Chemists and Druggists (AIOCD), the pharmaceutical market saw a growth of 7.7 per cent in May as against 3.5 per cent previous month. "We believe the impact of the FDC ban should lessen going ahead as companies launch new combinations," Religare research analyst Praful Bohra said in a report. On the other hand, the non-FDC category grew relatively better at 8.4 per cent in May as against 4.2 per cent in April, he added. The Centre recently banned 344 FDC drugs based on the findings of an expert panel. FDC drugs continued to witness weak growth, mostly in anti-infective and dermatology therapies. Therapy-wise, the anti-diabetic, neurology/CNS and cardiac segments outperformed the pharma market growth by ...

Govt taking steps to set up funds to promote pharma sector

Govt also looking at financial viability for providing Rs 200 cr each to three new bulk drug manufacturing parks

Why SC got it right on Novartis

The judgment will save taxpayers' money without hurting the pharma industry or R&D